DA-125, a New Antitumor Agent, Inhibits Topoisomerase II as Topoisomerase Poison and DNA Intercalator Simultaneously

다국어 초록 (Multilingual Abstract)

DA-125, a novel derivative of adriamycin, is known for its anti-cancer activity. In this study, the inhibitory mechanism of DA-125 on topoisomerase was investigated in the simian virus 40 (SV40) replicating CV-1 cell by studying the SV40 DNA replication intermediates and DNAtopoisomerase complexes. DNA-protein complexes that were formed in the drug-treated cells were quantitated by using a glass filter assay. SV40 DNA replication intermediates that were accumulated in the drug-treated CV-1 cell were analyzed in a high resolution gel. DA-125 did not accumulate B-dimers of SV40 DNA replication intermediates which were found in the adriamycin- treated CV-1 cells. DA-125 induced a dose-dependent formation of the DNA-protein complexes, while adriamycin did not. When adriamycin and etoposide (VP16) were added to the SV40-infected cells at the same time, adriamycin blocked the formation of the DNA-protein complexes induced by VP16 in a dose-dependent manner. However, DA-125 blocked the formation of the DNA-protein complexes induced by VP16 up to the maximum level of the DNA-protein complexes that were induced by DA-125 alone. Adriamycin and DA-125 did not inhibit the formation of the DNA-protein complexes that were caused by camptothecin, a known topoisomerase I poison. DA-125 is bifunctional in inhibiting topoisomerase II because it simultaneously has the properties of the topoisomerase II poison and the DNA intercalator. As a topoisomerase II poison, DA-125 alone induced dose-dependent formation of the DNA-protein complexes. However, as a DNA intercalator, it quantitatively inhibited the formation of the DNA-protein complexes induced by a strong topoisomerase II poison VP16. Furthermore considering that the levels of the DNA-protein complex induced by VP16 were decreased by DA- 125 in terms of the topoisomerase II poison, we suggest that DA-125 has a higher affinity to the drug-binding sites of DNA than VP16 has.

참고문헌 (Reference)

1 "the role of lipid peroxidation incardiac toxicity and tumor response. Science" 165-167, 1977

2 "Two-dimensional agarose gel analysis of simian virus 40DNA replication intermediates. Methods A companion tomethods in enzymology" 73-82, 1991

3 "Topoisomerase inhibitors can selectivelyinterfere with diferent stages of simian virus 40 DNAreplication. Mol. Cell. Biol." 4221-4227, 1986

4 "Theembryotoxicity of adriamycin in rat embroys in vitro. Toxicol.Appl. Pharmacol." 155-165, 1985

5 "Swivelingand decatenation of replicating simian virus 40 genome invivo. Mol. Cel. Biol." 515-521, 1988

6 "Selective extraction of polyoma DNA from infectedmouse cell cultures. J. Mol. Biol." 365-369, 1967

7 "Re- productive toxicity of DA-125, a new anthracycline anticancer agent: peri- and postnatal study in rats" 3 : 38-46, 1995

8 "Rapid evaluation of topoisomerase inhibitors caffeineinhibition of topoisomerases in vivo. Teratogen. Carcinogen.Mutagen." 41-52, 1990

9 "Papovavirus chromosomes as a model for mamalian DNAreplication. In . Mechanisms of DNA82 J.-W. Seo et al.replication and recombination. Alan R Liss" 423-427, 1983

10 "Newdevelopments on the mechanisms of action of antineoplasticdrugs. Life Sci." 1-14, 1979

11 "Intercalative antitumor drugs interfere with the breakage-reunion reaction of mamalian DNA topoisomerase I. J.Bio. Chem." 9182-9191, 1984a

12 "Inhibition of thereactions catalyzed by a type topoisomerase and a catenat-ing enzyme of Trypanosoma cruzi by DNA-intercalatingdrugs. EMBO J." 11-21, 1984

13 "Exposure to camptothecinbreaks leading and lagging strand simian virus 40 DNAreplication forks. Biochem. Biophys. Res. Commun." 135-140, 1990

14 "DNA Topoisomerase poisons as antitumor drugs.Annu. Rev. Biochem." 351-375, 1989

15 "DA-125, a novel antracycline derivative showing high-afinity DNA binding and topoisomerase II inhibitory activities, exerts cytotoxicity via c-Jun N-terminal kinase pathway" 47 : 511-518, 2001

16 "Arrest of segregation leads toaccumulation of highly interwined catenated dimers dissection of the final stages of SV40 DNA replication. Cel" 103-114, 1980

17 "Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin" 17 : 3613-3621, 1997

18 "A study on cardiotoxicity of DA-125" 9-19, 1993

19 "A phase II trial of DA-125, a novel anthracycline, in advanced non-small-cell lung cancer" 44 : 518-521, 1999